✦ LIBER ✦

DISEASE RECURRENCE AND PROGRESSION IN UNTREATED PATHOLOGIC STAGE T3 PROSTATE CANCER: SELECTING THE PATIENT FOR ADJUVANT THERAPY

✍ Scribed by Lowe, Bruce A.; Lieberman, Stephen F.

Book ID: 122415391
Publisher: Lippincott Williams and Wilkins
Year: 1997
Tongue: English
Weight: 649 KB
Volume: 158
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(01)64240-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

THE IMPACT OF ADJUVANT THERAPY AFTER RAD

THE IMPACT OF ADJUVANT THERAPY AFTER RADICAL PROSTATECTOMY FOR PATIENTS WITH PATHOLOGICAL T3b PROSTATE CANCER

✍ Siddiqui, Sameer A; Boorjian, Stephen A; Inman, Brant; Rangel, Laureano J; Bergs 📂 Article 📅 2008 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 185 KB

Influence of dna ploidy and adjuvant tre

Influence of dna ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy

✍ Craig A. Hawkins; Erik J. Bergstralh; Michael M. Lieber; Horst Zincke 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 800 KB

Androgen deprivation therapy for patient

Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy

✍ Gary D Grossfeld; Eric J Small; Deborah P Lubeck; David Latini; Jeanette M Broer 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Re: Pathologic Stage T2a and T2b Prostat

Re: Pathologic Stage T2a and T2b Prostate Cancer in the Recent Prostate-Specific Antigen Era: Implications for Unilateral Ablative Therapy

✍ Christian Bolenz; Alexandre E. Pelzer 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Re: Pathologic Stage T2a and T2b Prostat

Re: Pathologic Stage T2a and T2b Prostate Cancer in the Recent Prostate-Specific Antigen Era: Implications for Unilateral Ablative Therapy

✍ Guilherme Godoy; Daher C. Chade; Shahrokh F. Shariat 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Adjuvant Therapy for T3N0 Rectal Cancer

Adjuvant Therapy for T3N0 Rectal Cancer in the TME Era - How Do We Select High Risk Patients?

✍ Z. Zhang; J. Zhu; Y. Xu; W. Gu; J. Peng; G. Cai; G. Cai 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 43 KB